Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 135,158,768
  • Shares Outstanding, K 956,470
  • Annual Sales, $ 22,320 M
  • Annual Income, $ 8,318 M
  • 60-Month Beta 0.19
  • Price/Sales 6.15
  • Price/Cash Flow 20.27
  • Price/Book 32.15
Trade LLY with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 1.78
  • Number of Estimates 4
  • High Estimate 1.84
  • Low Estimate 1.72
  • Prior Year 1.48
  • Growth Rate Est. (year over year) +20.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
141.21 +0.07%
on 10/21/20
157.15 -10.08%
on 10/12/20
-9.87 (-6.53%)
since 09/21/20
3-Month
141.21 +0.07%
on 10/21/20
165.85 -14.80%
on 07/22/20
-23.99 (-14.51%)
since 07/21/20
52-Week
101.36 +39.41%
on 10/23/19
170.75 -17.24%
on 07/09/20
+33.40 (+30.95%)
since 10/21/19

Most Recent Stories

More News
In Pursuit of the Elusive Drug -- the Billion-Dollar Blockbuster

, /PRNewswire/ -- Enormous amounts of money exchange hands in the big pharma space as companies merge and are acquired — all in search of the next blockbuster drug. While the discovery of a blockbuster...

KBLM : 8.78 (-20.33%)
KBLMR : 0.3610 (-3.71%)
KBLMW : 0.2100 (-16.00%)
ALXN : 118.19 (-4.69%)
GILD : 60.21 (-0.56%)
LLY : 141.31 (-1.59%)
VRTX : 211.38 (-1.47%)
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Eli Lilly and Company and Encourages Investors with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - October 21, 2020) -  , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Eli Lilly and Company...

LLY : 141.31 (-1.59%)
Will Lilly (LLY) Witness Recovery in Sales in Q3 Earnings?

Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) third-quarter sales.

GILD : 60.21 (-0.56%)
MRK : 78.07 (-0.26%)
LLY : 141.31 (-1.59%)
GSK : 35.35 (-1.91%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eli Lilly and Company - LLY

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Eli Lilly and Company ("Eli Lilly" or the "Company") (NYSE: LLY).  Such investors are advised to contact at  ...

LLY : 141.31 (-1.59%)
ELI LILLY AND COMPANY ALERT: Bragar Eagel & Squire, P.C. is Investigating Eli Lilly and Company on Behalf of Eli Lilly Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Eli Lilly and Company (NYSE: LLY) on behalf of Eli Lilly stockholders. Our investigation...

LLY : 141.31 (-1.59%)
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Eli Lilly (LLY) closed at $143.59, marking a +0.55% move from the previous day.

LLY : 141.31 (-1.59%)
The Law Offices of Frank R. Cruz Continues Its Investigation of Eli Lilly and Company (LLY) on Behalf of Investors

The Law Offices of Frank R. Cruz continues its investigation of Eli Lilly and Company ("Eli Lilly" or the "Company") (NYSE: LLY) on behalf of investors concerning the Company's possible violations of federal...

LLY : 141.31 (-1.59%)
Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LLY : 141.31 (-1.59%)
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Eli Lilly and Company (LLY) on Behalf of Investors

Law Offices of Howard G. Smith continues its investigation on behalf of Eli Lilly and Company ("Eli Lilly" or the "Company") (NYSE: LLY) investors concerning the Company's possible violations of federal...

LLY : 141.31 (-1.59%)
AstraZeneca (AZN) Gets CHMP Nod for Forxiga in Heart Failure

The CHMP passes a favorable opinion for the approval of AstraZeneca's (AZN) Forxiga for the treatment of symptomatic chronic HFrEF in adults with and without type-II diabetes.

JNJ : 143.93 (-0.43%)
AZN : 51.57 (-1.19%)
LLY : 141.31 (-1.59%)
VRTX : 211.38 (-1.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their...

See More

Key Turning Points

2nd Resistance Point 144.07
1st Resistance Point 142.69
Last Price 141.31
1st Support Level 140.57
2nd Support Level 139.83

See More

52-Week High 170.75
Fibonacci 61.8% 144.24
Last Price 141.31
Fibonacci 50% 136.05
Fibonacci 38.2% 127.87
52-Week Low 101.36

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar